Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 10, 2026International Journal of Molecular SciencesOpen Access

Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions

View Full Paper
Ask AI
Bookmark
Share

Authors

TRTereza RůžičkováMKMichal KaščákZCZuzana Chyra

Discussion

Loading...

Member takes

Overview

Randomized trial decodes genomic interactions in Waldenström macroglobulinemia, suggesting improved therapies.

Key Points

  • This research aims to understand the genetic and epigenetic basis of Waldenström macroglobulinemia and its treatment responses.
  • Analyzed recurrent genetic alterations in Waldenström macroglobulinemia
  • Evaluated the impact of MYD88 and CXCR4 mutations
  • Assessed therapeutic strategies including Bruton’s tyrosine kinase inhibitors and proteasome inhibition.
  • Identification of MYD88 and CXCR4 mutations linked to disease prognosis and treatment response
  • Introduction of targeted therapies yielding improved patient outcomes
  • Treatment resistance identified as a prevalent clinical challenge.

Cite This Study

Růžičková et al. (2026) studied this question.

synapsesocial.com/papers/6a2901536f82f25be989db8ahttps://doi.org/10.3390/ijms27125173
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Waldenström macroglobulinemia: diagnosis and treatment2023 · 1 citations
  2. 2Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.2024 · 11 citations
  3. 3Current Approaches in the Management of Monoclonal Gammopathies: an approach to Waldenström Macroglobulinemia2024
  4. 4Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia2015 · 129 citations
  5. 5Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia2026